The Role of Pharmacogenetics in the Effectiveness of Rheumatoid Arthritis Treatment with Leflunomide
Open Access
Abstract
This article discusses rheumatoid arthritis (RA) as a chronic, systemic autoimmune disease leading to progressive joint damage and multi-organ complications. The complex pathogenesis of the disease is presented, involving the interaction of environmental, genetic, and immunological factors, including the role of autoantibodies and proinflammatory cytokines. Particular attention is paid to leflunomide, a disease-modifying antirheumatic drug (DMARD), which primarily works by inhibiting the DHODH enzyme, leading to reduced T and B cell proliferation. The additional anti-inflammatory properties of the drug’s active metabolite, teriflunomide, and its impact on signaling pathways related to the immune response are also discussed. This article examines the variability in patient responses to leflunomide treatment in terms of both efficacy and toxicity, with particular emphasis on the potential role of pharmacogenetic factors. It was pointed out that polymorphisms in genes related to drug metabolism, transport, and mechanism of action may influence the pharmacokinetics and safety of the therapy. It was also emphasized that the available data are primarily derived from observational studies and small cohorts, and the results are often inconsistent. Although some genetic variants and plasma teriflunomide concentrations show potential as predictors of treatment response, the current level of evidence does not support the routine use of pharmacogenetic testing in clinical practice. The article emphasizes that the pharmacogenetics of leflunomide represents a promising, yet still exploratory, avenue of research in the context of personalized RA therapy. It emphasizes the need for larger, well-designed clinical trials and the development of standardized guidelines, which would be necessary before the potential implementation of such strategies in routine clinical practice.Keywords
This publication has 60 references indexed in Scilit:
- Genetics of rheumatoid arthritisSeminars in Immunopathology, 2022
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis Care & Research, 2021
- DAS28‐CRP Cutoffs for High Disease Activity and Remission Are Lower Than DAS28‐ESR in Rheumatoid ArthritisACR Open Rheumatology, 2020
- Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid ArthritisArthritis Care & Research, 2020
- Translating Treatment Effects Between Rheumatoid Arthritis Activity Measures and American College of Rheumatology Responses in Direct Comparison TrialsArthritis Care & Research, 2019
- Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis PatientsCPT: Pharmacometrics & Systems Pharmacology, 2015
- Leflunomide in dialysis patients with rheumatoid arthritis—a pharmacokinetic studyClinical Rheumatology, 2012
- Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid levelEuropean Journal of Clinical Pharmacology, 2010
- Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patientsEuropean Journal of Clinical Pharmacology, 2008
- Mechanism of Action for Leflunomide in Rheumatoid ArthritisClinical Immunology, 1999